This study highlights the high real-world incidence of VTE in high-risk ambulatory cancer patients undergoing chemotherapy, emphasizing the potential benefit of targeted thromboprophylaxis.
Answers are grounded in this paper and cite their sources.
Supports consideration of targeted thromboprophylaxis in high-risk ambulatory cancer patients; extends observational data but leaves open randomized confirmation.
This large, contemporary, real-world analysis confirmed high rates of VTE in select patients with solid tumors and suggested that the incidence of VTE is high in the real-world setting. Awareness of the benefits of targeted thromboprophylaxis may result in a clinically significant reduction in the burden of VTE in this population.
No takes yet. Share an insight, caveat, or question.
Khorana et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: